Editorial Policies

Aims and Scope

Aim and Scope

The Journal's aim is to generalize scientific and practical achievements in a field of pharmacy and pharmacology, increase of scientific and practical qualification of pharmaceutical workers.

Objectives:

  • Coverage of new results in pharmacy and pharmacology.
  • Promotion of openness and availability of scientific works results of scientific and pedagogical workers, postgraduate students in different pharmacy fields.
  • Formation of a stable interest of scientific and pedagogical society, especially of beginner scientists to contemporary issues and problems of pharmacy and pharmacology, covered in the Journal.
  • Upgrade of professional level of pharmaceutical, scientific, and pedagogical workers, by publishing original articles, results of fundamental and applied researches, pointed at the development and study for the optimization of the pharmaceutical cluster, lectures, and reviews of literature on a wide spectrum of pharmaceutical problems, and the results of pre-clinical and experimental pharmacological investigations.

Enlargement of the audience of authors and readers building with the participation of Russian and foreign scientists and experts, who work in the pharmacy field, and doctors-pharmaceutists as well.

 

Sections

 

Peer Review Process

Рассмотрение рукописи

При получении рукописи ответственный секретарь редколлегии проводит проверку оформления рукописи.

Авторы рукописей, не соответствующих нашим требованиям, получают шаблонное электронное письмо с рекомендацией привести оформление рукописи в соответствие правилам журнала без детализации претензий. Если рукопись получена повторно и опять не отвечает всем требованиям по оформлению, она будет отклонена без рассмотрения.

После принятия решения о надлежащем оформлении рукописи, редакционная коллегия принимает решение о соответствии или несоответствии рукописи профилю журнала.

Принятая к рассмотрению рукопись будет направлена рецензентам.

Рецензирование

Все рукописи, поступившие в редакцию журнала «Фармация и фармакология», проходят обязательное двойное слепое рецензирование (рецензент не знает авторов рукописи, авторы рукописи не знаю рецензентов).

  1. Рецензирование осуществляется членами редакционной коллегии, редакционного совета, а также приглашенными рецензентами – ведущими специалистами в соответствующей области науки России и других стран. Решение о выборе рецензента для проведения экспертизы статьи принимает главный редактор, заместители главного редактора, ответственный секретарь. Срок рецензирования составляет  минимум  4 недели, но по просьбе рецензента он может быть продлен.
  2. Каждый рецензент имеет право отказаться от рецензии в случае наличия явного конфликта интересов, отражающегося на восприятии и интерпретации материалов рукописи. По итогам рассмотрения рукописи рецензент даёт рекомендации о дальнейшей судьбе статьи (каждое решение рецензента обосновывается):
    • статья рекомендуется к публикации в настоящем виде;
    • статья рекомендуется к публикации после исправления отмеченных рецензентом недостатков;
    • статья требует доработки и повторного рецензирования;
    • статья нуждается в дополнительном рецензировании другим специалистом;
    • статья не может быть опубликована в журнале.
  3. Если в рецензии содержатся рекомендации по исправлению и доработке статьи, редакция журнала направляет автору текст рецензии с предложением учесть их при подготовке нового варианта статьи или аргументировано (частично или полностью) их опровергнуть. Доработка статьи не должна занимать более 2 месяцев с момента отправки электронного сообщения авторам о необходимости внесения изменений. Доработанная автором статья повторно направляется на рецензирование.
  4. Ответы рецензентам авторы оформляют в отдельных файлах и загружают их на сайт, как дополнительные на вкладке "описание рукописи".  При отсутствии такого файла дальнейшая работа с рукописью приостанавливается, о чем авторы получают соответствующее уведомление.
  5. В случае отказа авторов от доработки материалов, они должны в письменной или устной форме уведомить редакцию о своем отказе от публикации статьи. Если авторы не возвращают доработанный вариант по истечении 3 месяцев со дня отправки рецензии, даже при отсутствии сведений от авторов с отказом от доработки статьи, редакция снимает её с учета. В подобных ситуациях авторам направляется соответствующее уведомление о снятии рукописи с регистрации в связи с истечением срока, отведенного на доработку.
  6. Если у автора и рецензентов возникли неразрешимые противоречия относительно рукописи, редколлегия вправе направить рукопись на дополнительное рецензирование. В конфликтных ситуациях решение принимает главный редактор.
  7. Решение об отказе в публикации рукописи принимается на заседании редакционной коллегии в соответствие с рекомендациями рецензентов. Статья, не рекомендованная решением редакционной коллегии к публикации, к повторному рассмотрению не принимается. Сообщение об отказе в публикации направляется автору по электронной почте.
  8. После принятия редколлегией журнала решения о допуске статьи к публикации редакция информирует об этом автора и указывает сроки публикации.
  9. Наличие положительной рецензии не является достаточным основанием для публикации статьи. Окончательное решение о публикации принимается редакционной коллегией.
  10. Оригиналы рецензий хранятся в редакции журнала в течение 5 лет. По официальному запросу копии рецензий могут быть переданы в ВАК. Редакция издания направляет копии рецензий в Министерство образования и науки Российской Федерации при поступлении в редакцию соответствующего запроса и в Российский Индекс Научного Цитирования после появления выпуска на сайте.

 

Publication Frequency

6 issues per year

 

Open Access Policy

«Pharmacy & Pharmacology» («Farmatsiya i farmakologiya») is an open access journal. All articles are made freely available to readers immediatly upon publication.

Our open access policy is in accordance with the Budapest Open Access Initiative (BOAI) definition - it means that articles have free availability on the public internet, permitting any users to read, download, copy, distribute, print, search, or link to the full texts of these articles, crawl them for indexing, pass them as data to software, or use them for any other lawful purpose, without financial, legal, or technical barriers other than those inseparable from gaining access to the internet itself.

For more information please read BOAI statement.

 

Indexing

Articles in «Pharmacy & Pharmacology» («Farmatsiya i farmakologiya») are indexed by several systems:

 

Publishing Ethics and Malpractice Statement

The Publication Ethics and Publication Malpractice Statement of the journal “Pharmacy & Pharmacology” are based on the Committee on Publication Ethics (COPE) Code of Conduct guidelines available at www.publicationethics.org and requirements for peer-reviewed medical journals (http://health.elsevier.ru/attachments/editor/file/ethical_code_final.pdf), elaborated by the Elsevier Publishing House (in accordance with international ethical rules of scientific publications)

 

1. Introduction

1.1. The publication in a peer reviewed learned journal, serves many purposes outside of simple communication. It is a building block in the development of a coherent and respected network of knowledge. For all these reasons and more it is important to lay down standards of expected ethical behaviour by all parties involved in the act of publishing: the author, the journal editor, the peer reviewer, the publisher and the society for society-owned or sponsored journal: «Pharmacy & Pharmacology» («Farmatsiya i farmakologiya»)

1.2. Publisher has a supporting, investing and nurturing role in the scholarly communication process but is also ultimately responsible for ensuring that best practice is followed in its publications.

1.3. Publisher takes its duties of guardianship over the scholarly record extremely seriously. Our journal programs record «the minutes of science» and we recognize our responsibilities as the keeper of those «minutes» in all our policies not least the ethical guidelines that we have here adopted.

2. Duties of Editors

2.1. Publication decision – The Editor of a learned «Pharmacy & Pharmacology» («Farmatsiya i farmakologiya»)  is solely and independently responsible for deciding which of the articles submitted to the journal should be published, often working on conjunction with the relevant society (for society-owned or sponsored journals). The validation of the work in question and its importance to researchers and readers must always underwrite such decisions. The Editor may be guided by the policies of the«Pharmacy & Pharmacology» («Farmatsiya i farmakologiya») journal’s editorial board and constrained by such legal requirements as shall then be in force regarding libel, copyright infringement and plagiarism. The editor may confer with other editors or reviewers (or society officers) in making this decision.

2.2. Fair play – An editor should evaluate manuscripts for their intellectual content without regard to race, gender, sexual orientation, religious belief, ethnic origin, citizenship, or political philosophy of the authors.

2.3. Confidentiality – The editor and any editorial staff of «Pharmacy & Pharmacology» («Farmatsiya i farmakologiya») must not disclose any information about a submitted manuscript to anyone other than the corresponding author, reviewers, potential reviewers, other editorial advisers, and the publisher, as appropriate.

2.4. Disclosure and Conflicts of interest

2.4.1. Unpublished materials disclosed in a submitted manuscript must not be used in an editor’s own research without the express written consent of the author. Privileged information or ideas obtained through peer review must be kept confidential and not used for personal advantage.

2.4.2. Editors should recuse themselves (i.e. should ask a co-editor, associate editor or other member of the editorial board instead to review and consider) from considering manuscripts in which they have conflicts of interest resulting from competitive, collaborative, or other relationships or connections with any of the authors, companies, or (possibly) institutions connected to the papers.

2.5. Vigilance over published record – An editor presented with convincing evidence that the substance or conclusions of a published paper are erroneous should coordinate with the publisher (and/or society) to promote the prompt publication of a correction, retraction, expression of concern, or other note, as may be relevant.

2.6.Involvement and cooperation in investigations – An editor should take reasonably responsive measures when ethical complaints have been presented concerning a submitted manuscript or published paper, in conjunction with the publisher (or society). Such measures will generally include contacting the author of the manuscript or paper and giving due consideration of the respective complaint or claims made, but may also include further communications to the relevant institutions and research bodies.

3. Duties of Reviewers

3.1. Contribution to Editorial Decisions – Peer review assists the editor in making editorial decisions and through the editorial communications with the author may also assist the author in improving the paper. Peer review is an essential component of formal scholarly communication, and lies at the heart of the scientific method. Publisher shares the view of many that all scholars who wish to contribute to publications have an obligation to do a fair share of reviewing.

3.2. Promptness – Any selected referee who feels unqualified to review the research reported in a manuscript or knows that its prompt review will be impossible should notify the editor of «Pharmacy & Pharmacology» («Farmatsiya i farmakologiya») and excuse himself from the review process.

3.3. Confidentiality – Any manuscripts received for review must be treated as confidential documents. They must not be shown to or discussed with others except as authorised by the editor.

3.4. Standard and objectivity – Reviews should be conducted objectively. Personal criticism of the author is inappropriate. Referees should express their views clearly with supporting arguments.

3.5. Acknowledgement of Sources – Reviewers should identify relevant published work that has not been cited by the authors. Any statement that an observation, derivation, or argument had been previously reported should be accompanied by the relevant citation. A reviewer should also call to the editor’s attention any substantial similarity or overlap between the manuscript under consideration and any other published paper of which they have personal knowledge.

3.6. Disclosure and Conflict of Interest

3.6.1. Unpublished materials disclosed in a submitted manuscript must not be used in a reviewer’s own research without the express written consent of the author. Privileged information or ideas obtained through peer review must be kept confidential and not used for personal advantage.

3.6.2. Reviewers should not consider manuscripts in which they have conflicts of interest resulting from competitive, collaborative, or other relationships or connections with any of the authors, companies, or institutions connected to the papers.

4. Duties of Authors

4.1. Reporting standards

4.1.1. Authors of reports of original research should present an accurate account of the work performed as well as an objective discussion of its significance. Underlying data should be represented accurately in the paper. A paper should contain sufficient detail and references to permit others to replicate the work. Fraudulent or knowingly inaccurate statements constitute unethical behaviour and are unacceptable.

4.1.2. Review and professional publication articles should also be accurate and objective, and editorial 'opinion’ works should be clearly identified as such.

4.2. Data Access and Retention – Authors may be asked to provide the raw data in connection with a paper for editorial review, and should be prepared to provide public access to such data (consistent with the ALPSP-STM Statement on Data and Databases), if practicable, and should in any event be prepared to retain such data for a reasonable time after publication.

4.3. Originality and Plagiarism

4.3.1. The authors should ensure that they have written entirely original works, and if the authors have used the work and/or words of others, this has been appropriately cited or quoted.

4.3.2. Plagiarism takes many forms, from ‘passing off’ another’s paper as the author’s own paper, to copying or paraphrasing substantial parts of another’s paper (without attribution), to claiming results from research conducted by others. Plagiarism in all its forms constitutes unethical publishing behaviour and is unacceptable.

4.4. Multiple, Redundant or Concurrent Publication

4.4.1. An author should not in general publish manuscripts describing essentially the same research in more than one journal of primary publication. Submitting the same manuscript to more than one journal concurrently constitutes unethical publishing behaviour and is unacceptable.

4.4.2. In general, an author should not submit for consideration in another journal a previously published paper.

4.4.3. Publication of some kinds of articles (eg, clinical guidelines, translations) in more than one journal is sometimes justifiable, provided certain conditions are met. The authors and editors of the journals concerned must agree to the secondary publication, which must reflect the same data and interpretation of the primary document. The primary reference must be cited in the secondary publication. Further detail on acceptable forms of secondary publication can be found at www.icmje.org.

4.5. Acknowledgement of Sources – Proper acknowledgment of the work of others must always be given. Authors should cite publications that have been influential in determining the nature of the reported work. Information obtained privately, as in conversation, correspondence, or discussion with third parties, must not be used or reported without explicit, written permission from the source. Information obtained in the course of confidential services, such as refereeing manuscripts or grant applications, must not be used without the explicit written permission of the author of the work involved in these services.

4.6. Authorship of the Paper

4.6.1. Authorship should be limited to those who have made a significant contribution to the conception, design, execution, or interpretation of the reported study. All those who have made significant contributions should be listed as co-authors. Where there are others who have participated in certain substantive aspects of the research project, they should be acknowledged or listed as contributors.

4.6.2. The corresponding author should ensure that all appropriate co-authors and no inappropriate co-authors are included on the paper, and that all co-authors have seen and approved the final version of the paper and have agreed to its submission for publication.

4.7. Hazards and Human or Animal Subjects (ICMJE - "Uniform Requirements for Manuscripts Submitted to Biomedical Journals").

4.7.1. If the work involves chemicals, procedures or equipment that have any unusual hazards inherent in their use, the author must clearly identify these in the manuscript.

4.7.2. If the work involves the use of animal or human subjects, the author should ensure that the manuscript contains a statement that all procedures were performed in compliance with relevant laws and institutional guidelines and that the appropriate institutional committee(s) have approved them. When reporting experiments on human subjects, authors should indicate whether the procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2000. If doubt exists whether the research was conducted in accordance with the Helsinki Declaration, the authors must explain the rationale for their approach, and demonstrate that the institutional review body explicitly approved the doubtful aspects of the study. When reporting experiments on animals, authors should be asked to indicate whether the institutional and national guide for the care and use of laboratory animals was followed.

4.7.3.  Authors should include a statement in the manuscript that informed consent was obtained for experimentation with human subjects, and it should be indicated in the published article.  The privacy rights of human subjects must always be observed. Patients have a right to privacy that should not be infringed without informed consent. Identifying information, including patients' names, initials, or hospital numbers, should not be published in written descriptions, photographs, and pedigrees unless the information is essential for scientific purposes and the patient (or parent or guardian) gives written informed consent for publication. Informed consent for this purpose requires that a patient who is identifiable be shown the manuscript to be published. Authors should identify Individuals who provide writing assistance and disclose the funding source for this assistance. Identifying details should be omitted if they are not essential. Complete anonymity is difficult to achieve, however, and informed consent should be obtained if there is any doubt. For example, masking the eye region in photographs of patients is inadequate protection of anonymity. If identifying characteristics are altered to protect anonymity, such as in genetic pedigrees, authors should provide assurance that alterations do not distort scientific meaning and editors should so note.

4.8. Disclosure and Conflicts of Interest

4.8.1. All authors should disclose in their manuscript any financial or other substantive conflict of interest that might be construed to influence the results or interpretation of their manuscript. All sources of financial support for the project should be disclosed.

4.8.2. Examples of potential conflicts of interest which should be disclosed include employment, consultancies, stock ownership, honoraria, paid expert testimony, patent applications/registrations, and grants or other funding. Potential conflicts of interest should be disclosed at the earliest possible stage.

4.9. Fundamental errors in published works – When an author discovers a significant error or inaccuracy in a published work, it is the author’s obligation to promptly notify the editor of «Pharmacy & Pharmacology» («Farmatsiya i farmakologiya») journal and cooperate with Publisher to retract or correct the paper, If the editor or the publisher learn from a third party that a published work contains a significant error, it is the obligation of the author to promptly retract or correct the paper.

 

5. Duties of the Publisher (and if relevant, Society)

5.1. Publisher should adopt policies and procedures that support editors, reviewers and authors of «Pharmacy & Pharmacology» («Farmatsiya i farmakologiya») in performing their ethical duties under these ethics guidelines. The publisher should ensure that the potential for advertising or reprint revenue has no impact or influence on editorial decisions.

5.2. The publisher should support «Pharmacy & Pharmacology» («Farmatsiya i farmakologiya») journal editors in the review of complaints raised concerning ethical issues and help communications with other journals and/or publishers where this is useful to editors.

5.3. Publisher should develop codes of practice and inculcate industry standards for best practice on ethical matters, errors and retractions.

5.4. Publisher should provide specialized legal review and counsel if necessary.

 

Publication Fees

Publication in «Pharmacy & Pharmacology» («Farmatsiya i farmakologiya») is free of charge for all the authors.

The journal doesn't have any Arcticle processing charges.

The journal doesn't have any Article submission charges.

 

Preprint and postprint Polic

Prior to acceptance and publication in «Pharmacy & Pharmacology» («Farmatsiya i farmakologiya»), authors may make their submissions available as preprints on personal or public websites.

As part of submission process, authors are required to confirm that the submission has not been previously published, nor has been submitted. After a manuscript has been published in «Pharmacy & Pharmacology» («Farmatsiya i farmakologiya») we suggest that the link to the article on journal's website is used when the article is shared on personal or public websites.

Glossary (by SHERPA)

Preprint - In the context of Open Access, a preprint is a draft of an academic article or other publication before it has been submitted for peer-review or other quality assurance procedure as part of the publication process. Preprints cover initial and successive drafts of articles, working papers or draft conference papers.
 
Postprint - The final version of an academic article or other publication - after it has been peer-reviewed and revised into its final form by the author. As a general term this covers both the author's final version and the version as published, with formatting and copy-editing changes in place.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies